MedTrace Logo

A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)

NCT07698899 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-07-13

No results posted yet for this study

Summary

The purpose of this study is to find out whether 177Lu-DPTA-omburtamab is a safe treatment for children and adolescents with recurrent/refractory medulloblastoma or another type of cancer with CNS metastases.

Conditions

  • Recurrent Medulloblastoma
  • Refractory Medulloblastoma
  • CNS Metastases
  • Central Nervous System Metastasis

Interventions

BIOLOGICAL

25 mCi 177Lu- DTPA-omburtamab

The dose of DTPA-omburtamab will be decided by the dose escalation design

Sponsors & Collaborators

Principal Investigators

  • Sameer Farouk Sait, MBBS · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
3 Years
Max Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-02
Primary Completion
2030-06-02
Completion
2030-07-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07698899 on ClinicalTrials.gov